ClinicalTrials.gg
WithdrawnNCT01245816Updated Apr 24, 2015

A Trial of Low Dose Sulindac Combined With Eflornithine in Patients With Familial Adenomatous Polyposis (FAP)

A Phase 3 interventional study of Eflornithine plus Sulindac and Eflornithine plus Placebo in Familial Adenomatous Polyposis, sponsored by Cancer Prevention Pharmaceuticals, Inc.. Withdrawn. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-04-24.

Sponsored by Cancer Prevention Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this phase III study is to evaluate the safety and efficacy of the combination of eflornithine and sulindac compared to single agent sulindac or eflornithine in reducing the number of polyps in patients with familial adenomatous polyposis (FAP).

02

Conditions studied

  • Familial Adenomatous Polyposis

Keywords

  • colon polyps
03

In context

Adenomatous Polyposis Coli

92 studies on the registry are indexed under Adenomatous Polyposis Coli; 28 are open to participants now.

Browse Adenomatous Polyposis Coli studies →

Lead sponsor

Cancer Prevention Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of phenotypic Familial Adenomatous Polyposis (FAP) of the colorectum based on meeting the criteria in one of two groups: Group 1-Greater than 100 adenomatous colorectal polyps prior to age 40. Group 2-Greater than 10 adenomatous polyps and age \<40 or greater than 25 polyps and age >40; combined with a dominant family history or genotype: More than 100 polyps in a first-degree relative; More than 25 polyps in 2 relatives in 2 generations, including a first-degree family member; Genetic diagnosis in a relative; Genetic diagnosis by in vitro synthesized truncated protein or similar assay.
  • No colorectal surgery or prior colon surgery for polyposis at least 1 year prior (total abdominal colectomy with ileal-rectal anastomosis, or total proctocolectomy with ilea pouch-anal reconstruction.
  • Baseline endoscopy

    1. If no prior colorectal surgery, at least 3 polyps in a cluster each ≥ 2 mm in diameter; or
    2. If rectum is in situ and to be assessed, baseline rectal segment endoscopy documenting 3 or more rectal polyps each at least 2 mm in diameter in a defined cluster and/or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of rectum
    3. If ileal pouch neo-rectum is in place, 3 or more pouch polyps in a cluster ≥ 2 mm in diameter, or at least 6 polyps, ≥ 2 mm in diameter, in the distal 10 cm of pouch.
    4. Clinical/pathological grading of duodenal polyps will utilize the Spigelman Classification.
  • Hematopoietic: no significant hematologic dysfunction; WBC ≥3,000/mm3; count ≥100,000/mm3; ≥10g/dL; no known or prior clinical coagulopathy.
  • Hepatic: ≤ 1.5 times ; and ALT ≤ 1.5 times ULN; Alkaline phosphatase ≤ 1.5 times ULN.
  • Renal: No significant renal dysfunction; creatinine ≤ 1.5 times ULN.
  • Hearing: no hearing loss that affects everyday life.
  • Not pregnant or nursing.
  • Negative serum pregnancy test if female of .
  • Absence of gross blood in stool.
  • Fertile patients must use effective .
  • Stool occult blood either negative or minimal (1+).
  • No prior to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; no NSAID associated symptoms of gastritis.
  • No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated successfully with antibiotics (as documented by an endoscopy.
  • No invasive within the past 5 years except stage I or II colon or rectal cancer or resected nonmelanomatous skin cancer.
  • No other significant medical or psychiatric problems that would preclude study participation.
  • No chronic adrenocorticosteroids.
  • No prior pelvic irradiation.
  • At least 3 months since prior agents.
  • Patients may not be receiving or plan to receive .
  • Concomitant NSAID use outside this study may not exceed 4 days per month.
  • Use of 81 mg daily aspirin or 650 mg aspirin not more than once a week.
  • No concurrent warfarin, fluconazole, or lithium.
  • Must be willing and able to sign .

Exclusion criteria

Exclusion Criteria:

  • High Risk for cardiovascular disease including clinical diabetes mellitus (Type I or II) requiring glycemic medications; Prior personal history of cardiovascular disease or, two or more of the following - hypertension or use of anti-hypertensive medications, hyperlipidemia or use of lipid-lowering medications or current smoker.
  • Hearing loss that affects everyday life and or for which a hearing aid is required.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Eflornithine plus Sulindac

    Eflornithine 500 mg and Sulindac 150 mg

    Drug: Eflornithine plus Sulindac

  • Active comparator
    Elfornithine plus Placebo

    Eflornithine 500 mg and Placebo

    Drug: Eflornithine plus Placebo

  • Active comparator
    Sulindac plus Placebo

    Sulindac 150 mg and Placebo

    Drug: Sulindac plus Placebo

Interventions

  • DrugEflornithine plus Sulindac

    Drug pages: Eflornithine · Sulindac

    Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day

    Also known as: DFMO

  • DrugEflornithine plus Placebo

    Drug page: Eflornithine

    Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day

    Also known as: DFMO

  • DrugSulindac plus Placebo

    Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day

06

What researchers measure

Primary outcomes

  1. Efficacy of Eflornithine plus Sulindac compared to Eflornithine alone and Sulindac alone determined by change in the number of polyps 2 mm or greater in a defined focal area of the rectum or pouch at baseline and after completion of the study treatment.

    Time frame: 6 months from the start of treatment.

Secondary outcomes

  1. Change in number of polyps 2 mm or greater in the distal 10 cm of rectum or pouch.

    Time frame: 6 months from the start of treatment.

  2. Qualitative change in overall colon/rectum/pouch polyp burden (number and size).

    Time frame: 6 months from the start of treatment.

  3. Presence of high grade dysplasia or villous adenoma in any polyp resected.

    Time frame: 6 months from the start of treatment.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2010
First posted
Nov 23, 2010
Start
Mar 2011
Primary completionEst.
May 2013
CompletionEst.
Jun 2013
Last update
Apr 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01245816
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
First posted
Nov 23, 2010
Start date
Mar 2011
Primary completion
May 2013 (estimated)
Completion
Jun 2013 (estimated)
Last update
Apr 24, 2015

Study contacts

Alfred M. Cohen, M.D.
study director · Cancer Prevention Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eflornithine · Sulindac

Start the discussion